Metabolic Diseases Research Center, Research Institute for Prevention of Non-Communicable Diseases, Qazvin University of Medical Sciences, Qazvin, Iran.
Department of Urology, Qazvin University of Medical Sciences, Qazvin, Iran.
World J Urol. 2023 Sep;41(9):2465-2471. doi: 10.1007/s00345-023-04512-x. Epub 2023 Jul 17.
Benign prostatic hyperplasia (BPH) is the main prevalent disorder in men over forty years, usually revealing itself with lower urinary tract symptoms. Despite the existence of different treatments, the incidence of BPH is increasing, so further studies for better management are a necessity. This research was designed to assay the effectiveness of nano-micellar curcumin on biomedical indicators of patients with BPH.
The present research was a double-blind, randomized, and placebo-controlled trial that enrolled fifty-two patients with BPH between June 2021 and December 2021. Participants were randomized to receive 160 mg/d nano-micellar curcumin (n = 26) or placebo (n = 26) as soft gel during 3 months. Primary end point was changes in International Prostate Symptoms Score (IPSS). Data gathering was occurred using a standard inquiry form and measuring other biomedical parameters based on routine laboratory techniques. To compare the distribution of demographics and covariates, independent t-test and Chi-square were used.
Nano-micellar curcumin had significant effect on IPSS (p value: 0.010), low effect on high-sensitive C-reactive protein (hs-CRP) (p value: 0.032), and low to intermediate effect on malondialdehyde (MDA) (p value: 0.014) level as secondary end points after the intervention. The effect of nano-micellar curcumin on other parameters was negligible.
Overall, this trial indicated 3-month intake of nano-micellar curcumin had considerable effects on IPSS as the most common clinical symptom and also two biomedical parameters including serum hs-CRP and MDA.
http://www.irct.ir : IRCT20170430033730N3.
良性前列腺增生（BPH）是 40 岁以上男性的主要常见疾病，通常表现为下尿路症状。尽管有不同的治疗方法，但 BPH 的发病率仍在上升，因此需要进一步研究以更好地管理。本研究旨在检测纳米胶束姜黄素对 BPH 患者生物医学指标的疗效。
本研究是一项双盲、随机、安慰剂对照试验，纳入了 2021 年 6 月至 2021 年 12 月间的 52 名 BPH 患者。参与者被随机分为每天接受 160mg 纳米胶束姜黄素（n=26）或安慰剂（n=26）的软凝胶，为期 3 个月。主要终点是国际前列腺症状评分（IPSS）的变化。数据收集采用标准查询表进行，并根据常规实验室技术测量其他生物医学参数。为了比较人口统计学和协变量的分布，使用独立 t 检验和卡方检验。
纳米胶束姜黄素对 IPSS 有显著影响（p 值：0.010），对超敏 C 反应蛋白（hs-CRP）有低影响（p 值：0.032），对丙二醛（MDA）有低到中等影响（p 值：0.014），这些都是干预后的次要终点。纳米胶束姜黄素对其他参数的影响可以忽略不计。
总的来说，这项试验表明，3 个月的纳米胶束姜黄素摄入对 IPSS（最常见的临床症状）以及血清 hs-CRP 和 MDA 等两个生物医学参数有显著影响。
